Hawthorn Pharmaceuticals cuts global deal with CoPlex
by MBJ Staff
Published: September 13,2011
MADISON — Hawthorn Pharmaceuticals Inc. has struck an exclusive global licensing deal with CoPlex Therapeutics on hawAD14, a preclinical oral small molecule candidate for the treatment of Alzheimer’s and other neurodegenerative diseases.
Under the terms of the agreement, Hawthorn will receive an exclusive worldwide license to develop and commercialize hawAD14 and will be responsible for funding all future development.
“In terms of the discovery’s uniqueness, it’s one of only few programs in the world demonstrating multiple protective effects against the predominant pathophysiologic pathways of Alzheimer’s disease,” said Rob Lewis, chief scientific officer at Hawthorn Pharmaceuticals.
“We are in the process of conducting the necessary preclinical studies in order to file an IND with the FDA,” said Max Draughn, Hawthorn Pharmaceuticals’ CEO.
To sign up for Mississippi Business Daily Updates, click here.
FOLLOW THE MBJ ON TWITTERMy Tweets
Top Posts & Pages
- Alcorn president launches new customer service task force
- NEW IN MADISON COUNTY — Mississippi Bio-Medical Business Collaboratory to be introduced Friday
- David Duval, former British Open winner, joins Sanderson Farms field
- Court rules against Greenwood councilwoman; must give up office
- GreenTech holds grand opening of neighborhood electric vehicle plant
- Turner Grain’s bankruptcy will help consolidate lawsuits alleging breach of contract
- Cochran continues to reach out to African American voters
- Peoples Bank reports quarterly loss due to bad loans
- Senators write letter over Waters of the United States proposal